VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

IHC 2021 | Update on potential drugs targeting delta and kappa opioid receptors

Amynah Pradhan, PhD, University of Illinois at Chicago, Chicago, IL, talks on preclinical research that is being done targeting delta and kappa receptors in migraine treatment. Dr Pradhan discusses the clinical trials being carried out by Trevena on delta opioid receptor ligands. Preclinical kappa opioid receptor research is also being carried out with kappa antagonists being developed or in clinical trials for stress disorders which may be useful in migraine treatment. This interview took place during the International Headache Congress 2021.